Mushroom World team Verified: November 15, 2026 ~4 min read

Mushrooms, heart health and longevity: what human studies show

How everyday culinary mushrooms — button, oyster and shiitake — relate to vascular health and mortality: we review the 21-year Malmö cohort, NHANES analysis, a 22-study systematic review and a 2026 RCT.

#nutrition#heart#longevity#ergothioneine#research

When mushrooms are marketed as "functional food", they are often reduced to a list of isolated compounds. Yet long before reaching our kitchen, a fungus lives a complex life in forest litter or wood. To survive in an environment full of bacteria, oxidative stress and competitors, fungi evolved a distinctive biochemistry: the thiol antioxidant ergothioneine, branched cell-wall beta-glucans, ergosterol and natural sterols.

Remarkably, humans — who cannot synthesize ergothioneine at all — retained a dedicated transporter protein, OCTN1, that actively pulls this fungal molecule from food and holds it in tissues for weeks. On that level, mushrooms on our plate are not a passing wellness trend but an ancient metabolic partnership. The scientific question is straightforward: does this biology translate into measurable human outcomes?

What the 21-year Malmö cohort showed

The strongest observational signal came not from food questionnaires, but from direct blood measurements. In the Swedish prospective Malmö Diet and Cancer cohort (study card, Heart, 2020, PMID 31672783), researchers measured 112 plasma metabolites in 3,236 participants free of cardiovascular disease and diabetes at baseline and followed them for a median of 21.4 years.

Across all 112 metabolites, ergothioneine showed the strongest association with a health-conscious food pattern — and predicted lower risk per 1 SD increase:

  • coronary artery disease: 15% lower risk (HR 0.85);
  • cardiovascular mortality: 21% lower (HR 0.79);
  • all-cause mortality: 14% lower (HR 0.86).

The honest boundary is clear: an observational cohort shows association, not proof of causation. Blood ergothioneine may partly reflect a broader pattern of people who cook fresh meals and include mushrooms regularly.

Mortality and diet: NHANES and a 5-cohort meta-analysis

In 2021, a Penn State team tested dietary mushroom intake directly against all-cause mortality (study card, Nutrition Journal, 2021, PMID 34548082):

  • In the US NHANES 2003–2014 cohort (n = 30,378; median follow-up 6.7 years; 2,855 deaths), the point estimate leaned protective but was not statistically significant: adjusted HR = 0.84 (95% CI 0.67–1.06).
  • Pooling five prospective cohorts (601,893 participants), mushroom consumption was associated with a modest, statistically significant 6% reduction in all-cause mortality: pooled RR = 0.94 (95% CI 0.91–0.98).

This is a sober, data-respecting finding: culinary mushrooms are not an elixir of immortality, yet across large populations they consistently accompany a slightly lower mortality risk.

Whole mushrooms and cardiometabolic risk: a 22-study review

What happens to blood pressure, glucose and blood lipids when people eat whole mushrooms such as button mushrooms, oyster mushrooms or shiitake? Uffelman et al. (study card, Nutrients, 2023, PMID 36904079) reviewed 22 human studies (11 interventional and 11 observational):

  • In experimental trials, limited evidence pointed to lower triglycerides and inflammatory marker hs-CRP.
  • Evidence for blood pressure, fasting glucose and HbA1c remained inconsistent or insufficient.
  • Most earlier trials scored poorly on NHLBI quality criteria, prompting the authors to call for rigorous randomized controlled trials.

An honest null result: the 2026 oyster mushroom RCT

Exactly such a registered, double-blind, placebo-controlled trial was published in 2026 by the University of Bonn (study card, Nutrition & Metabolism, PMID 42071226). For 4 weeks, 46 adults with moderately elevated LDL cholesterol consumed a daily drink containing 8.4 g of oyster mushroom powder (delivering 3 g of fungal beta-glucans — matching the EFSA threshold for oat beta-glucans) or placebo.

The primary endpoint — LDL cholesterol — did not change. Serum ergosterol confirmed compliance, and post-hoc analysis suggested lower cholesterol absorption markers (particularly in women), yet the main takeaway is candid: branched fungal beta-1,3/1,6-glucans are structurally distinct from linear oat beta-glucans and did not lower LDL over 4 weeks.

What this means in practice

  1. Whole mushrooms work best as real food, not a quick-fix pill. Swapping part of red or processed meat for button mushrooms, oyster mushrooms or shiitake naturally lowers energy density while adding potassium, selenium, fiber and ergothioneine.
  2. Do not expect a rapid drop in cholesterol in one month. Lipid and blood pressure management relies on overall diet, movement and medical care; mushrooms are a steady supporting food.
  3. Species variety beats a single "super-mushroom". Oyster species (especially golden oyster) and shiitake are rich in ergothioneine, while button mushrooms are affordable year-round.

Limits of knowledge

  • The largest mortality and cardiovascular findings come from observational cohorts, where residual lifestyle confounding cannot be fully ruled out.
  • Short trials (4–8 weeks) may miss slower metabolic shifts; fungal beta-glucans require longer, well-powered clinical studies.

Sources

  1. Nutrients 2023: systematic review of whole mushroom consumption and cardiometabolic risk (PMID 36904079)
  2. Heart 2020: ergothioneine and cardiovascular mortality in the Malmö cohort (PMID 31672783)
  3. Nutrition Journal 2021: mushroom intake and mortality in NHANES + meta-analysis (PMID 34548082)
  4. Nutrition & Metabolism 2026: RCT of oyster mushroom powder and LDL cholesterol (PMID 42071226)